#United States #New York #Faruqi Law #Aquestive Therapeutics #AQST

Important Alert for Investors in Aquestive Therapeutics

Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued a significant reminder for investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST). If you have purchased or acquired securities of Aquesta between June 16, 2025, and January 8, 2026, the deadline for participating in a federal securities class action lawsuit is fast approaching on May 4, 2026. This class action has been initiated against the company, and investors must act before the deadline to seek the role of lead plaintiff.

Faruqi & Faruqi has a storied history of advocating for investors' rights, having recovered hundreds of millions of dollars since its founding in 1995. The firm's experience underscores the importance of staying informed about legal actions that might affect shareholders, particularly those associated with allegations of federal securities law violations.

What Led to the Class Action?

The basis for the lawsuit revolves around allegations that Aquestive Therapeutics and its executives made misleading statements regarding the company's New Drug Application (NDA) for Anaphylm, a sublingual film for treating anaphylaxis. Specifically, the complaint claims that the company failed to disclose critical deficiencies identified by the FDA, which ultimately resulted in a substantial decline in stock price.

On January 9, 2026, news broke that the FDA had informed Aquestive of these deficiencies, stating that they precluded any further discussion about labeling and post-marketing commitments. Following the announcement, the company's stock plummeted by $2.30 per share, a staggering 37.04% drop, closing at $3.91 per share on that day. For investors who relied on the company's prior representations, this was a significant and damaging fallout.

Understanding Your Legal Rights

Potential plaintiffs in this matter must understand their legal options. The lead plaintiff in such class action lawsuits is typically the individual or entity that has suffered the largest financial loss and is capable of representing other members of the class. It's crucial to recognize that whether or not you serve as the lead plaintiff, your ability to partake in any potential recovery from the case will remain unaffected.

The law firm encourages all investors who have experienced losses to reach out directly to discuss their circumstances and understand their rights. Faruqi & Faruqi invites anyone with relevant information, including former employees or whistleblowers, to contact their office. Such insights can be invaluable in building a strong case against Aquestive.

Next Steps for Investors

For those affected by the recent drop in Aquestive's stock and who are contemplating action, the firm has provided a direct line for inquiries. Interested investors can contact Josh Wilson, a senior partner at Faruqi & Faruqi, at either 877-247-4292 or 212-983-9330 (Ext. 1310). Additionally, informative resources are available via their website at www.faruqilaw.com/AQST.

As the deadline of May 4, 2026, approaches, investors should be proactive in addressing their legal rights and the implications of this ongoing litigation. In-depth understanding and timely action will be vital in ensuring that investors can safeguard their interests amidst these developments. Staying informed through Faruqi & Faruqi’s updates on platforms like LinkedIn and X (formerly Twitter) will also help investors remain abreast of any changes or significant developments in this case.

Disclaimer: This article is intended for informational purposes only and should not be construed as legal advice. Individuals experiencing financial loss should consider reaching out to a qualified legal professional to discuss their specific situation.